Patents by Inventor Hshiou-ting Liu
Hshiou-ting Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11524012Abstract: The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the solid lyophilized form. Furthermore, the present invention provides compositions comprising Compound I, or a pharmaceutically acceptable salt and/or solvate thereof and therapeutic use of the composition.Type: GrantFiled: August 5, 2021Date of Patent: December 13, 2022Assignee: SENHWA BIOSCIENCES, INC.Inventors: Hshiou-ting Liu, John Soong
-
Publication number: 20220062294Abstract: The present invention includes formulation comprising 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) or a pharmaceutically acceptable salt thereof for use in treating cancer.Type: ApplicationFiled: September 2, 2021Publication date: March 3, 2022Inventors: Hshiou-ting LIU, John SOONG
-
Publication number: 20210046082Abstract: The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I). Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.Type: ApplicationFiled: August 14, 2020Publication date: February 18, 2021Inventor: Hshiou-ting LIU
-
Publication number: 20190374550Abstract: The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the solid lyophilized form. Furthermore, the present invention provides compositions comprising Compound I, or a pharmaceutically acceptable salt and/or solvate thereof and therapeutic use of the composition.Type: ApplicationFiled: February 15, 2019Publication date: December 12, 2019Inventors: Hshiou-ting LIU, John Soong
-
Patent number: 9957282Abstract: The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.Type: GrantFiled: December 14, 2015Date of Patent: May 1, 2018Assignee: SENHWA BIOSCIENCES, INC.Inventors: David M. Ryckman, Iching Grace Yu, Hshiou-ting Liu
-
Publication number: 20170166590Abstract: The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.Type: ApplicationFiled: December 14, 2015Publication date: June 15, 2017Inventors: David M. Ryckman, Iching Grace Yu, Hshiou-ting Liu
-
Patent number: 8030458Abstract: An IgG1? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: GrantFiled: September 26, 2008Date of Patent: October 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams
-
Patent number: 7863427Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immnoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: GrantFiled: April 12, 2007Date of Patent: January 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Yi-Feng Zheng, Pratap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Publication number: 20090087865Abstract: An IgG1? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams
-
Publication number: 20070218506Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immnoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: ApplicationFiled: April 12, 2007Publication date: September 20, 2007Applicant: DADE BEHRING INC.Inventors: Yi-Feng Zheng, Pratrap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Patent number: 7220842Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immunoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: GrantFiled: April 5, 2004Date of Patent: May 22, 2007Assignee: Dade Behring Inc.Inventors: Yi-Feng Zheng, Pratap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Patent number: 7189582Abstract: Compounds are disclosed comprising a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, linked to a sirolimus compound at position 26 or at position 32. Such sirolimus compounds comprising an immunogenic carrier can be employed to raise both polyclonal and monoclonal antibodies to the sirolimus compound. Polyclonal antibodies are also disclosed, which are raised against a compound wherein a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, is linked to a sirolimus compound at position 32. The above antibodies and sirolimus compounds comprising a label can be used in assays for the detection of sirolimus compounds.Type: GrantFiled: April 27, 2005Date of Patent: March 13, 2007Assignee: Dade Behring Inc.Inventors: Jian Chen, Holger Keim, Hshiou-ting Liu, Yi Feng Zheng, Yali Yang, Cathy K. Worley
-
Publication number: 20060246518Abstract: Compounds are disclosed comprising a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, linked to a sirolimus compound at position 26 or at position 32. Such sirolimus compounds comprising an immunogenic carrier can be employed to raise both polyclonal and monoclonal antibodies to the sirolimus compound. Polyclonal antibodies are also disclosed, which are raised against a compound wherein a moiety, such as a poly(amino acid), a non-poly(amino acid) label moiety, or a non-poly(amino acid) immunogenic carrier, is linked to a sirolimus compound at position 32. The above antibodies and sirolimus compounds comprising a label can be used in assays for the detection of sirolimus compounds.Type: ApplicationFiled: April 27, 2005Publication date: November 2, 2006Inventors: Jian Chen, Holger Keim, Hshiou-ting Liu, Yi Zheng, Yali Yang, Cathy Worley
-
Publication number: 20060223998Abstract: A general method for the synthesis of OH-LSD and its analogs has been successfully developed. This method is convenient and efficient and allows preparation of a series of OH-LSD analogs with linkers attached at various (C-8, N-6 or N-1) positions.Type: ApplicationFiled: March 30, 2005Publication date: October 5, 2006Inventors: Fang-Jie Zhang, Hshiou-ting Liu
-
Patent number: 7115383Abstract: Methods, compositions and kits are disclosed. The compounds disclosed comprise an amphetamine moiety and a methamphetamine moiety linked together by a first linking group. A second linking group depends from the first linking group and comprises a functional group. The distance of the amphetamine moiety and the methamphetamine moiety from the point of linkage of the second linking group to the first linking group is approximately the same. The compounds may be linked to labels and used in assays for the detection of amphetamine and/or methamphetamine in samples suspected of containing these drugs.Type: GrantFiled: March 22, 2004Date of Patent: October 3, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Richard F. Parrish, Johnny Valdez, Hshiou-ting Liu
-
Patent number: 7078495Abstract: An IgG1 ? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: GrantFiled: August 3, 1999Date of Patent: July 18, 2006Assignee: Dade Behring Inc.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams
-
Patent number: 7037669Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/or for a methamphetamine for use in assays for the determination of an amphetamine and/or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.Type: GrantFiled: March 22, 2004Date of Patent: May 2, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Khaled A. Yamout, Donald E. Berger, Jr., Mae W. Hu, Hshiou-ting Liu
-
Patent number: 6991911Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.Type: GrantFiled: December 15, 2003Date of Patent: January 31, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Hshiou-ting Liu
-
Publication number: 20050221405Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immunoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: ApplicationFiled: April 5, 2004Publication date: October 6, 2005Inventors: Yi-Feng Zheng, Pratap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Publication number: 20050208604Abstract: Methods, compositions and kits are disclosed. The compounds disclosed comprise an amphetamine moiety and a methamphetamine moiety linked together by a first linking group. A second linking group depends from the first linking group and comprises a functional group. The distance of the amphetamine moiety and the methamphetamine moiety from the point of linkage of the second linking group to the first linking group is approximately the same. The compounds may be linked to labels and used in assays for the detection of amphetamine and/or methamphetamine in samples suspected of containing these drugs.Type: ApplicationFiled: March 22, 2004Publication date: September 22, 2005Inventors: Yi Zheng, Richard Parrish, Johnny Valdez, Hshiou-ting Liu